Can Anthera Whet Investors Appetite For Biotech IPOs?
Almost any biotech IPO was a huge success back in the 2001-2006 years. Since the start of the current downturn in the stock prices and stock indexes for about two years we have not seen any single successful biotech IPO. The credit crunch adversely affected the Biotech industry. Almost all of the companies which operate in the biotech sector do depend strongly on outside financing. They hardly generate any income during the times they research their pharmaceuticals or other biotech products. During a time where the stock exchanges experienced fresh money where many reaped the benefits not one of the biotech companies ever tried to launch a biotech IPO. In the last year the conditions changed a bit and investors started to act more boldly in their decisions. Since the first half of 2009 several biotech companies like Seattle Genetics, Inspire Pharmaceuticals, Cumberland Pharma and others, successfully got their money from the public investors on the stock exchanges. It is no surprise th
Related Questions
- What other funds in the current plan lineup are closed to new investors? Will any of the closed funds be available to participants who invest in the new self-directed mutual fund window?
- How critical is the stock market sentiment for IPOs to attract big interest from investors?
- Why do Non-U.S. Investors buy Reg-S stock?
